A Single Patient Compassionate Use of MBM-02 (Tempol) for the Treatment of Prostate Cancer

Available (expanded access)

Conditions studied: Prostate Cancer

In brief

A single patient compassionate use clinical trial for the use of MBM-02 (TEMPOL) for the treatment of prostate cancer. The single patient will be exposed to orally administered TEMPOL for up to 12 months at a maximum total daily dose of 800mg.

Key facts

Study ID

NCT04337099

Run by

Matrix Biomed, Inc.

Last updated by the study team

2021-05-05

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Biochemical Recurrent Prostate Cancer

Where it is running

• Prostate Oncology Specialists — Marina del Rey, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.